For media inquiries, please contact Matt Middleman at: matt@lifescipublicrelations.com
Subscribe to Samumed’s newsletter and
media coverage

2018

Date	Title
Aug 06	Samumed Closes on $438 Million in Equity Financing
Jul 27	Samumed Presents Positive Preclinical Data on SM07883 at 2018 Alzheimer’s Association International Conference® (AAIC®)
Jul 17	Samumed to Present Preclinical Data on SM07883, a Potential First-in-Class Alzheimer’s Disease Candidate, at the Alzheimer’s Association International Conference® (AAIC®) 2018
Jun 29	Samumed Announces Presentation of Clinical Data Analysis on SM04690 for Treatment of Knee Osteoarthritis at International Workshop on Osteoarthritis Imaging (IWOAI) 2018 Conference
Jun 20	Samumed Presents Clinical and Preclinical Data at European League Against Rheumatism (EULAR) 2018 Annual Congress
Jun 08	Samumed Announces Multiple Presentations at the European League Against Rheumatism (EULAR) 2018 Annual Congress
May 31	Samumed to Present Data on Multiple Product Candidates in Five Presentations at The Orthobiologic Institute (TOBI) 2018 Annual Symposium
May 11	Samumed Announces Presentation at the 2018 American Thoracic Society (ATS) International Conference
May 07	Samumed Presented Multiple Abstracts Supporting Potential Disease Modification at the Osteoarthritis Research Society International (OARSI) 2018 World Congress
May 03	Scrip Pharma Intelligence: Samumed CMO Hopes to Reach Drug Approvals via the Wnt Pathway
Apr 27	Samumed's CEO Presents at Unite to Cure: Fourth International Vatican Conference
Apr 23	Samumed’s Osteoarthritis and Tendinopathy Research Selected for Multiple Presentations at the 2018 Osteoarthritis Research Society International (OARSI) World Congress

2017

Date	Title
Dec 18	Samumed Doses First Patient in Phase 1 Trial of SM04690 for Treatment of Degenerative Disc Disease
Dec 11	Samumed Doses First Patient in Phase 1 Trial of SM08502 for Treatment of Advanced Solid Tumors
Nov 17	Samumed Announces Collaboration with L'Oréal for Development of SM05253 for Anti-Wrinkle Skin Care Applications
Nov 06	Samumed Announces Results of Phase 2 Trial of SM04690 Demonstrating Evidence of Cartilage Regeneration in Patients with Knee Osteoarthritis
Oct 31	Samumed Initiates Phase 1b Trial of SM04755 for Treatment of Psoriasis
Oct 24	Samumed Announces 52-week Phase 2 Osteoarthritis Data Supporting the Potential of SM04690 as a Disease Modifying Drug
Oct 05	Nature Reviews Rheumatology: Wnt Inhibitor Shows Potential as a DMOAD
Aug 01	Samumed's Osteoarthritis Research Selected for an Oral Presentation at a Gordon Research Conference
Jul 27	Samumed Successfully Completed 52-week Phase 2 Study for Treatment of Osteoarthritis of the Knee
Jul 25	PulmonaryFibrosisNews.com: FDA Grants Orphan Drug Designation to Samumed’s Investigational SM04646 for IPF Treatment
Jul 24	Samumed Receives Orphan Drug Designation from FDA for SM04646 as a Treatment for Idiopathic Pulmonary Fibrosis (IPF)
Jul 21	Samumed Successfully Completes Phase 1 Study for Potential Topical Treatment for Chronic Tendinopathy
Jul 20	Samumed and IHS Markit Present Analysis of Medicare Claims Data for Knee OA
Jul 17	Samumed Successfully Completed Phase 1 Study for the Potential Treatment of Idiopathic Pulmonary Fibrosis
Jun 20	Samumed Selected for Four Presentations at European League Against Rheumatism (EULAR) 2017 Annual Meeting
Jun 20	Pharmaceutical-Technology.com: EULAR 2017: Osteoarthritis Pipeline Product Shows Promise
Apr 02	BusinessInsider.com: A $12 Billion Startup You've Probably Never Heard Wants to Cure Baldness and Smooth Out Your Wrinkles
Mar 15	Samumed’s CEO Presents at Near Future Summit 2017
Mar 06	Samumed Presented Data on Increases in Hair Follicles Observed in Its Phase 2 Biopsy Study for a Potential Treatment of Androgenetic Alopecia (AGA) at Annual Meeting of the American Academy of Dermatology (AAD)

2016

Date	Title
Nov 16	Samumed Presents Data For Potential Topical Treatment for Psoriasis
Nov 15	Samumed's Wnt Pathway Modulator SM04690 Shows Potential as a Disease Modifying Treatment for Osteoarthrits (OA) of the Knee
Nov 15	Samumed Presents Data for a Small Molecule Modulator of the Wnt Pathway as a Potential Treatment for Degenerative Disc Disease
Nov 14	Samumed Presents Data for a Small Molecule Modulator of Wnt Pathway as a potential topical treatment for Chronic Tendinopathy
Nov 14	Samumed, LLC Presents Data for Small Molecule Modulator of Wnt Pathway as a Potential Topical Treatment for Scleroderma
Nov 01	Samumed Selected for Seven Presentations in Five Therapeutic Areas at American College of Rheumatology 2016 Annual Meeting
Oct 25	Samumed Successfully Completes a Phase II Androgenetic Alopecia (“AGA”) Biopsy Trial Studying Regeneration of Hair Follicles
Oct 13	Samumed's CEO Presents at the Forbes Healthcare Summit
Sep 17	Samumed’s CEO presents their regenerative medicine platform at the Royal Society of Medicine’s 13th Medical Innovations Summit
May 05	CNBC Interview with Samumed's CEO
Apr 13	Forbes.com: Cure Baldness? Heal Arthritis? Erase Wrinkles? An Unknown Billionaire's Quest To Reverse Aging
Apr 13	Forbes.com: The Forbes Global Game Changers List: Bezos, Zuckerberg And More Business Leaders Transforming The World
Apr 04	Samumed presents at the 2016 World Congress of the Osteoarthritis Research Society International (OARSI)
Mar 07	Samumed presents at the annual meeting of the American Academy of Dermatology (AAD) Safety and Efficacy results from its Phase 2 androgenetic alopecia (AGA) trial
Mar 05	Forbes.com: Experimental Drug Shows Early Promise In Treating Male Baldness

2015

Date	Title
Dec 04	Samumed announces increases in both hair count and hair density observed in its Phase II study for a potential treatment of androgenetic alopecia (AGA)
Nov 23	Samumed completes phase II study for its potential treatment of Androgenetic Alopecia: safety data shows no serious adverse events in treated patients
Nov 18	Samumed, LLC to announce clinical data on potential treatment of androgenetic alopecia at the World Congress for Hair Research
Nov 18	Patient advocacy group Creaky Joints® covers Samumed’s osteoarthritis presentations at ACR
Nov 12	U.S. Congressman Scott Peters visits the Samumed corporate office
Nov 09	Samumed, LLC Announces Successful Modulation Of The Wnt Pathway For Potential Cartilage Regeneration
Nov 06	Samumed Begins Enrollment In A Phase II Clinical Trial For The Treatment Of Osteoarthritis (OA) Of The Knee Using A Novel Wnt Pathway Modulator
Nov 03	Samumed, LLC To Announce Potential Disease Modifying Treatment Of Osteoarthritis At American College of Rheumatology (ACR) Annual Meeting

web stats